MX2022012128A - Comprimido complejo oral que comprende sitagliptina, dapagliflozina y metformina. - Google Patents

Comprimido complejo oral que comprende sitagliptina, dapagliflozina y metformina.

Info

Publication number
MX2022012128A
MX2022012128A MX2022012128A MX2022012128A MX2022012128A MX 2022012128 A MX2022012128 A MX 2022012128A MX 2022012128 A MX2022012128 A MX 2022012128A MX 2022012128 A MX2022012128 A MX 2022012128A MX 2022012128 A MX2022012128 A MX 2022012128A
Authority
MX
Mexico
Prior art keywords
dapagliflozin
sitagliptin
metformin
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2022012128A
Other languages
English (en)
Inventor
Taek Kwan Kwon
Ho Taek Im
Jin Wook Tak
Bo Sik Kim
Yong Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2022012128A publication Critical patent/MX2022012128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con un aspecto, se proporcionan un comprimido compuesto y un método de preparación del comprimido compuesto, en donde el comprimido compuesto puede incluir una primera capa que incluye gránulos secos que incluyen sitagliptina o una sal farmacéuticamente aceptable de la misma, o, un hidrato de la misma, y dapagliflozina o una sal farmacéuticamente aceptable de la misma, o un hidrato de la misma, y una segunda capa que incluye gránulos húmedos que incluyen metformina o una sal farmacéuticamente aceptable de la misma y dióxido de silicio coloidal.
MX2022012128A 2020-03-30 2021-03-12 Comprimido complejo oral que comprende sitagliptina, dapagliflozina y metformina. MX2022012128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200038568A KR102856843B1 (ko) 2020-03-30 2020-03-30 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제
PCT/KR2021/003080 WO2021201461A1 (ko) 2020-03-30 2021-03-12 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제

Publications (1)

Publication Number Publication Date
MX2022012128A true MX2022012128A (es) 2022-10-18

Family

ID=77929083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012128A MX2022012128A (es) 2020-03-30 2021-03-12 Comprimido complejo oral que comprende sitagliptina, dapagliflozina y metformina.

Country Status (10)

Country Link
US (1) US20230149314A1 (es)
EP (1) EP4112047B1 (es)
JP (1) JP7787088B2 (es)
KR (1) KR102856843B1 (es)
CN (1) CN115297847A (es)
AU (1) AU2021249767A1 (es)
BR (1) BR112022019539A2 (es)
MX (1) MX2022012128A (es)
WO (1) WO2021201461A1 (es)
ZA (1) ZA202210630B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
EP4212150A1 (en) * 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
CN115813874B (zh) * 2022-12-29 2024-07-23 越洋医药开发(广州)有限公司 一种口服三方组合降糖双释片的制备方法及其制剂
KR20240107660A (ko) * 2022-12-30 2024-07-09 주식회사 대웅제약 이나보글리플로진 및 메트포르민을 포함하는 약학 조성물
EP4556001A1 (en) * 2023-11-14 2025-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. A bilayer tablet composition comprising dapagliflozin and metformin
KR20250154775A (ko) * 2024-04-22 2025-10-29 제이피바이오 주식회사 다파글리플로진, 리나글립틴 및 메트포르민을 포함하는 안정성이 향상된 약제학적 제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1465612A1 (en) * 2001-11-06 2004-10-13 Ranbaxy Laboratories Limited Controlled release tablets of metformin
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
EP2691083B1 (en) * 2011-03-29 2017-08-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition of sitagliptin
WO2013110085A1 (en) * 2012-01-20 2013-07-25 Handa Pharmaceuticals, Llc Oral dosage forms for delivering metformin and sitagliptin
KR20160111237A (ko) * 2015-03-16 2016-09-26 한미약품 주식회사 메트포르민 및 시타글립틴을 포함하는 경구용 복합제제
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
KR20180078762A (ko) * 2016-12-30 2018-07-10 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
KR102369679B1 (ko) * 2017-09-29 2022-03-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
KR102204439B1 (ko) * 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
ZA202210630B (en) 2025-12-17
KR102856843B1 (ko) 2025-09-08
CN115297847A (zh) 2022-11-04
EP4112047A1 (en) 2023-01-04
EP4112047A4 (en) 2024-03-27
US20230149314A1 (en) 2023-05-18
EP4112047C0 (en) 2025-08-20
WO2021201461A1 (ko) 2021-10-07
AU2021249767A1 (en) 2022-09-22
JP7787088B2 (ja) 2025-12-16
BR112022019539A2 (pt) 2022-11-16
JP2023519532A (ja) 2023-05-11
KR20210121599A (ko) 2021-10-08
EP4112047B1 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
MX2022012128A (es) Comprimido complejo oral que comprende sitagliptina, dapagliflozina y metformina.
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
AR032037A1 (es) Particulas de textura enmascarada que contienen un ingrediente activo
IT962125B (it) Composti silicio organici solforati e procedimento per la loro produ zione
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
AR117510A1 (es) COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS
MX2024005822A (es) Compuestos macrociclicos con actividad inhibidora de la farnesiltransferasa.
MX2021013980A (es) Compuesto para el tratamiento de gota o hiperuricemia.
CY1120240T1 (el) Απο του στοματος χορηγουμενο παρασκευασμα δισκιου ενωσης τετρακυκλινης
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2023011176A (es) Tratamiento de hidradenitis supurativa con orismilast.
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
AR119159A1 (es) Tratamientos de angioedema
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
MX2019004938A (es) Cápsula compleja que contiene esomeprazol y método de preparación de esta.
CL2025001560A1 (es) Composición farmacéutica para prevención o tratamiento de úlcera péptica relacionada a fármacos que comprende zastaprazán
TR201914043A1 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
JPWO2022177029A5 (es)
UY38028A (es) Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y su uso para el tratamiento del dolor